Back to top

Image: Bigstock

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Read MoreHide Full Article

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

Now that we know how important earnings and earnings surprises are, it's time to show investors how to take advantage of these events to boost their returns by utilizing the Zacks Earnings ESP filter.

The Zacks Earnings ESP, Explained

The Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate.

The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.

Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Regeneron?

The final step today is to look at a stock that meets our ESP qualifications. Regeneron (REGN - Free Report) earns a #3 (Hold) eight days from its next quarterly earnings release on October 31, 2024, and its Most Accurate Estimate comes in at $12.13 a share.

Regeneron's Earnings ESP sits at +2.9%, which, as explained above, is calculated by taking the percentage difference between the $12.13 Most Accurate Estimate and the Zacks Consensus Estimate of $11.79. REGN is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

REGN is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is Novartis (NVS - Free Report) .

Novartis is a Zacks Rank #2 (Buy) stock, and is getting ready to report earnings on October 29, 2024. NVS' Most Accurate Estimate sits at $1.97 a share six days from its next earnings release.

The Zacks Consensus Estimate for Novartis is $1.94, and when you take the percentage difference between that number and its Most Accurate Estimate, you get the Earnings ESP figure of +1.51%.

Because both stocks hold a positive Earnings ESP, REGN and NVS could potentially post earnings beats in their next reports.

Find Stocks to Buy or Sell Before They're Reported

Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Regeneron Pharmaceuticals, Inc. (REGN) - free report >>

Novartis AG (NVS) - free report >>

Published in